Brief: Crinetics Announces FDA Approval Of Palsonify (Paltusotine) For The Treatment Of Adults With Acromegaly
25/09/2025 22:51
Sept 25 (Reuters) - Crinetics Pharmaceuticals Inc CRNX.O: CRINETICS ANNOUNCES FDA APPROVAL OF PALSONIFY™ (PALTUSOTINE) FOR THE TREATMENT OF ADULTS WITH ACROMEGALY Source text: ID:nGNX23ccmD Further company coverage: CRNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crinetics Pharmaceuticals
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Crinetics Q2 revenue jumps on PALSONIFY launch, withdraws guidance
Brief: Crinetics Pharmaceuticals Q2 Net Income USD -120.855 Million